Depomed Inc

Depomed — Merger or Acquisition (December 2017)

13 slides from Depomed's merger presentation, Dec 4, 2017

  1. Slide 1: Forward Looking Statements

    Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning established by the Private Securities Litigation Reform Act of 1995 ("Act"). The forward-looking statements are intended to qualify under provisions of the federal securities laws for "safe harbor"

  2. Slide 2: A Clear Strategy for Growth

    A Clear Strategy for Growth Executing on a Three Pillar Growth Strategy 3 MAINTAIN a Strong/Profitable NUCYNTA Franchise GROW Neurology and Pain Businesses BUILD a New Specialty Business Collegium Transaction December 2017 90 Rep Salesforce Operational October 2017 Cosyntropin Depot Transaction Anno

  3. Slide 3: Collegium Deal Supports Maintaining a Strong/Profitable NUCYNTA Franchise

    Collegium Deal Supports Maintaining a Strong/Profitable NUCYNTA® Franchise Opioid Market Dynamics Demanded Evaluation of Multiple Options: Option 1: Grow into Current Pain Organization through Business Development Activity: Extensive analysis and discussion resulted in conclusion that differentiated

  4. Slide 4: NUCYNTA Commercialization Agreement

    NUCYNTA® Commercialization Agreement At closing, Collegium Pharmaceutical will obtain the rights to commercialize NUCYNTA® Depomed will retain ownership of the NDAs and be responsible for NUCYNTA® product supply Depomed will maintain responsibility for pediatric post-marketing studies Collegium will

  5. Slide 5: Collegium: Ideal Partner to Take NUCYNTA to the Next Level

    Collegium: Ideal Partner to Take NUCYNTA® to the Next Level Recognized as an emerging leader in pain management and committed to building a leading pain company Xtampza® ER is the fastest growing Extended Release branded opioid Strong home office, commercial and managed care infrastructures Salesfor

  6. Slide 6: Headquarters Restructuring and Relocation Aligns with New Business Model

    Headquarters Restructuring and Relocation Aligns with New Business Model Headquarters Relocation in 2018: Evaluating Mid-West and East Coast Sites Provides Improved Access to Pharmaceutical Talent Current Footprint: 60,000 square feet housing 120 employees 380 person salesforce New Footprint: Approx

  7. Slide 7: Financial Overview

    Financial Overview August Moretti SVP Finance and Chief Financial Officer

  8. Slide 8: NUCYNTA Cash Flows and Reduction in Expenses Will Improve EBITDA and EBITDA Margins

    NUCYNTA® Cash Flows and Reduction in Expenses Will Improve EBITDA and EBITDA Margins Transaction Provides Strong Cash Flows to Depomed from NUCYNTA® Sales In Connection with this Transaction, Depomed to Eliminate its Pain Salesforce and Terminate Brand Marketing Expense for NUCYNTA® Depomed to Reduc

  9. Slide 9: Potential for EBIDTA Improvement

    Potential for EBIDTA Improvement Assumed NUCYNTA Net Sales* 11 $220mm $240mm $260mm Potential EBIDTA Enhancement Resulting from Collegium Transaction $50 $37 $24 Royalty Payment Change to Grünenthal ($3.2) - $1.2 Net EBIDTA Improvement $46.8 $37 $25.2 Guidance to be Provided in 2018 *For illustrativ

  10. Slide 10: Potential for EBIDTA Improvement

    Potential for EBID Improvement Assumed NUCYNTA Net Sales* $220mm $240mm $260mm Potential EBIDTA Enhancement Resulting from Collegium Transaction $50 $37 $24 Royalty Payment Change to Griinenthal ($3.2) - $1.2 Net EBIDTA Improvement $46.8 $37 $25.2 *For illustrative purposes only Guidance to be Provi

  11. Slide 11: Summary

    Summary Arthur Higgins President and Chief Executive Officer

  12. Slide 12: Delivering on Our Strategy for Growth and Creating Shareholder Value

    Delivering on Our Strategy for Growth and Creating Shareholder Value 14 MAINTAIN a Strong/Profitable NUCYNTA Franchise GROW Neurology and Pain Businesses BUILD a New Specialty Business Collegium Transaction December 2017 90 Rep Salesforce Operational October 2017 Cosyntropin Depot Transaction Announ

  13. Slide 13: Delivering on Our Strategy for Growth and Creating Shareholder Value

    Delivering on Our Value : ooU GROW Neurology and Pain Businesses BUILD a New Specialty Business Cosyntropin/Depot Transaction Announced November 2017 Seoeromen

Depomed — Merger or Acquisition (December 2017) on 6ix